证券代码：002737 证券简称：葵花药业 葵花药业集团股份有限公司投资者关系活动记录表 编号：2016-005 | --- | --- | --- | |----------------|-------------------|-----------------------------------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 调研单位： 东吴证券 调研人员：张智聪 调研单位： 金百镕投资 调研人员：马学进 | | 人员姓名 | | | | 时间 | 2016 年 8 月 29 | 日 10 时 00 分 | | 地点 | 公司 2 楼会议室 | | | 上市公司接待人 | 公司董事会秘书 | 田 艳 女士 证券事务代表 周广阔 先生 | | 员姓名 | | | | 投资者关 ...

证券代码：002737 证券简称：葵花药业 葵花药业集团股份有限公司投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |----------------|--------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 西南证券 周平 | | | 人员姓名 | | | | 时间 | 2016 年 4 月 15 | 日 9:00 | | 地点 | 公司四楼会议室 | | | | | | | 上市公司接待人 | 公司董事会秘书 田 艳女士 | | | 员姓名 | | 公司证券事务代表 周广阔先生 | | 投资者关系活动 | 1. | 在药品价格放开的背景下，公司的产品价格管控策略 | | 主要内容介绍 | ...

证券代码：002737 证券简称：葵花药业 编号：2016-002 | --- | --- | --- | |----------------|-----------------------|----------------------------------------------------------| | | | | | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华夏基金 刘志军 | | | 人员姓名 | | | | 时间 | 2016 年 4 月 | 21`日 9:00 | | 地点 | 公司四楼会议室 | | | 上市公司接待人 | 公司董事会秘书 田 | 艳女士 | | 员姓名 | | 公司证券事务代表 周广阔先生 | | 投资者关系活动 | 1 、公司 2015 | 年年报中存货同比上升原因 | | 主要内容介绍 | 存货同比增加，主要系 | 2015 年公司并购企业 ...

证券代码：002737 证券简称：葵花药业 编号：2016-006 | --- | --- | --- | |----------------|---------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 千合资本 殷萌萌 | | | 人员姓名 | 华商基金 陈 恒 | | | | 前海旗隆 冯 超 | | | | 新同方投资 李 静 | | | | 淡水泉投资 周玖洲 | | | | 招商基金 梅 梅 | | | | 平安证券 梁 欢 | | | 时间 | 2016 年 12 月 | 8 日 14 时 | | 地点 | 公司四楼会议室 | | | 上市公司接待人 | 公司董事会秘书 | 田 艳女士 | | 员姓名 | 公司证券事务代表 | 周广阔先生 ...

Group 1: Company Overview - Aohua Pharmaceutical has developed a strong brand presence over 20 years, focusing on children's medicine and modern traditional Chinese medicine [2][3] - The company aims to be a leader in high-quality children's medicine and modern traditional Chinese medicine, with a strategic focus on "variety → brand → category" [2][3] Group 2: Market Position and Strategy - The domestic children's medicine market accounts for only 5% of the overall pharmaceutical industry, while children represent approximately 16.6% of the national population, indicating significant growth potential [6] - Aohua Pharmaceutical is positioned as the largest player in the children's medicine sector, benefiting from a strong brand, extensive sales network, and continuous optimization of operations [6] Group 3: Research and Development - In 2017, Aohua Pharmaceutical invested 104 million yuan in R&D, with plans to adjust future investments based on ongoing projects [5] - Key R&D projects include: - Pediatric cough syrup, which is undergoing efficacy trials for additional indications [3][4] - Pediatric anti-cold granules, based on traditional Chinese medicine, with clinical studies already initiated [4] - Liver protection tablets, expanding indications to include drug-induced liver injury and alcoholic liver disease [4] Group 4: Future Growth and Product Development - The company plans to maintain a focus on children's medicine as a key profit growth area, with a product strategy that includes a diverse range of categories [3][5] - Aohua Pharmaceutical will continue to enhance its core brands while also investing in new drug development, ensuring a balanced approach to growth [5][6]

Group 1: Market Performance and Strategy - The company's OTC segment accounts for approximately 80% of total revenue, indicating a strong market presence and competitive advantage in this area [46]. - The company is optimistic about the children's medication market due to increasing consumer spending and the rise of non-traditional diseases among children [46]. - The company has a dedicated BD team focused on product acquisition, employing a strategy of "buy, modify, connect, research, and代" [46]. Group 2: Product Development and Future Outlook - The company is expanding its product line by introducing new OTC products, particularly in children's medicine and health supplements, with a focus on rare diseases and mental health products [46]. - The gross margin for health products is expected to be lower than that of pharmaceuticals initially, but it is anticipated to improve as the business scales [46]. - The company is actively investing in probiotics and aims to establish a core category in the health sector [46].

Financial Performance - The company's revenue for Q3 2022 was ¥980,317,708.73, representing a 7.31% increase year-over-year[7] - Net profit attributable to shareholders for Q3 2022 was ¥107,852,983.83, up 15.48% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥100,840,067.15, reflecting a 17.72% increase year-over-year[7] - Total revenue for the third quarter reached ¥3,229,486,011.71, an increase of 7.1% compared to ¥3,015,249,787.60 in the same period last year[27] - Operating profit for the quarter was ¥676,117,380.51, up from ¥461,840,781.33, reflecting a significant growth in profitability[29] - Net profit attributable to shareholders was ¥509,070,636.55, compared to ¥400,698,884.02 in the previous year, marking an increase of 27.1%[29] - Total comprehensive income for the period reached ¥536,667,354.95, an increase from ¥452,603,515.47 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,069,591,824.46, an increase of 11.44% from the end of the previous year[7] - Total assets increased to ¥6,069,591,824.46 from ¥5,635,203,544.61, representing a growth of 7.7%[26] - Total liabilities rose to ¥2,031,965,910.63, up from ¥1,700,079,714.65, indicating a 19.5% increase[26] - Non-current liabilities decreased to ¥423,900,656.06 from ¥447,473,643.37, showing a reduction of 5.3%[26] - The company's equity attributable to shareholders increased to ¥3,818,440,313.62 from ¥3,709,407,064.33, reflecting a growth of 2.9%[26] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥781,191,722.90, showing a significant increase of 98.30%[7] - Cash flow from operating activities generated a net amount of ¥781,191,722.90, compared to ¥393,947,375.76 in the previous period, reflecting a significant increase[33] - Cash inflow from investment activities totaled ¥1,693,694,743.41, up from ¥550,736,735.82 in the previous period[36] - Cash outflow for investment activities was ¥2,284,923,425.69, compared to ¥1,342,260,378.97 in the previous period, resulting in a net cash flow from investment activities of -¥591,228,682.28[36] - Cash flow from financing activities resulted in a net outflow of -¥246,516,872.36, compared to -¥154,740,979.24 in the previous period[36] - The ending balance of cash and cash equivalents was ¥1,257,534,070.46, down from ¥1,095,589,385.35 in the previous period[36] Shareholder Information - The basic earnings per share for Q3 2022 was ¥0.19, an increase of 18.75% compared to the same period last year[7] - Basic earnings per share increased to ¥0.88 from ¥0.69, while diluted earnings per share also rose to ¥0.87 from ¥0.69[32] - The major shareholder, Guo Yanbin, reduced his stake in the company by over 1%[16] - The company is actively involved in internal equity structure adjustments among its major shareholders[19] Operational Highlights - The company reported a significant increase in other income, which reached ¥53,815,852.18, up 109.97% from the previous year[12] - The company established a wholly-owned subsidiary as part of its expansion strategy[19] - The company provided guarantees for its controlling subsidiaries, indicating ongoing support for its business operations[19] - Research and development expenses for the quarter were ¥94,784,131.15, slightly down from ¥94,944,223.49, indicating a stable investment in innovation[27] - The total operating costs for the quarter were ¥2,593,122,681.80, an increase from ¥2,538,566,324.06, reflecting a rise in operational expenses[27] Current Assets - As of September 30, 2022, the total current assets amounted to CNY 3,817,636,582.59, an increase from CNY 3,392,928,097.05 at the beginning of the year[20] - The cash and cash equivalents were reported at CNY 1,257,534,070.46, down from CNY 1,320,129,979.45 at the start of the year[20] - The trading financial assets increased significantly to CNY 1,404,000,000.00 from CNY 668,687,524.34[20] - Inventory levels rose to CNY 795,940,189.96 compared to CNY 709,638,552.08 at the beginning of the year[20] - The company reported accounts receivable of CNY 193,095,017.50, slightly down from CNY 194,746,659.98[20]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[22] - The net profit attributable to shareholders was RMB 200 million, up 10% compared to the same period last year[22] - The management has set a revenue target of RMB 2.5 billion for the full year 2022, reflecting a growth of 12%[22] - The company's operating revenue for the reporting period was ¥2,249,168,302.98, representing a 7.01% increase compared to the same period last year[29] - Net profit attributable to shareholders was ¥401,217,652.72, marking a 30.56% increase year-over-year[29] - The net profit after deducting non-recurring gains and losses was ¥357,652,282.42, which is a 36.92% increase compared to the previous year[29] - The net cash flow from operating activities was ¥492,363,334.38, reflecting a 9.39% increase from the same period last year[29] - Basic earnings per share increased to ¥0.70, up 32.08% from ¥0.53 in the previous year[29] Market Strategy and Expansion - The company has outlined a market expansion strategy targeting a 25% increase in market share by the end of 2023[22] - User data indicates a growth of 20% in the customer base, reaching 5 million active users[22] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[22] - A new product line is expected to launch in Q4 2022, projected to contribute an additional RMB 500 million in revenue[22] - The company plans to strengthen its strategic investments in children's medicine and adult chronic disease medication categories[42] - The company aims to maintain and consolidate its leading position in the OTC market through a combination of brand marketing and strategic investments[42] Research and Development - The company plans to invest RMB 300 million in R&D for new products and technologies in the upcoming year[22] - The company has nearly 60 children's medicine products, establishing a leading competitive advantage in the industry[40] - The company focused on brand building, enhancing the competitive barriers of its "Xiao Kuihua" children's medicine and "Kuihua" adult medicine brands[45] - The company launched new health products, including two straw products in the health sector, with the blueberry lutein soft candy achieving over 1 million GMV in its first month[53] Operational Efficiency - The company emphasized the optimization of production processes and supply chain management to improve efficiency and reduce costs[48] - The company established a financial shared service center to enhance decision-making efficiency through standardized and information-based management[54] - The company implemented a new sales model combining "factory + internet platform + terminal" to enhance user engagement and sales efficiency[49] Environmental Responsibility - The company has established environmental management systems and has dedicated personnel responsible for managing pollution control facilities[110] - The company has implemented a self-monitoring plan for environmental compliance and conducted monitoring activities as required[115] - The company adheres to national and local environmental regulations, ensuring that wastewater, waste gas, noise, and solid waste are managed to meet discharge standards[110] - The company has not experienced any pollution incidents or administrative penalties during the reporting period[116] - The company implemented measures to reduce carbon emissions, achieving significant energy savings through steam condensate recovery and solar power installations[117] Risks and Challenges - The company is facing risks related to industry policy changes and raw material price fluctuations, which may impact future performance[5] - The company is facing increased regulatory pressures in the pharmaceutical industry due to deeper reforms, which may impact future operations and profitability[85] - The company faces risks from fluctuations in raw material prices, with significant increases observed in traditional Chinese medicine materials and chemical raw materials due to the COVID-19 pandemic and inflation[86] - Management risks have increased as the company's business model and scale expand, necessitating higher management standards across various functions[87] Corporate Governance - The company did not distribute cash dividends or issue new shares during the reporting period[99] - The employee stock ownership plan includes 26 marketing management personnel holding a total of 4.18 million shares, representing 0.72% of the company's total equity[103] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[126] - The company reported no significant related party transactions during the reporting period[141] - The company has appointed new executives and announced resignations of supervisors and independent directors[170] Financial Management - The company has a total of 120,000 million in entrusted financial management, all of which is from self-owned funds[150] - The company has engaged in various financial product investments, including participation in fund subscriptions and profit distribution announcements[170] - The company has completed the performance of certain guarantees, indicating successful fulfillment of obligations[146] - The company has plans for future entrusted financial management, indicating ongoing investment strategies[150]

Group 1: Event Announcement - The company will participate in the "2022 Investor Online Collective Reception Day Activity and Performance Briefing" on May 12, 2022, from 14:30 to 16:30 [1] - The event is organized by the Heilongjiang Provincial Listed Companies Association in collaboration with Shenzhen Panorama Network Co., Ltd. [1] - The event aims to enhance information transparency and improve investor relations management [1] Group 2: Company Representatives - The representatives from the company include Chairwoman Guanyuxiu, Deputy General Manager Haiyang, Financial Officer Wuchunhong, and Board Secretary Zhouguangkuo [1] Group 3: Investor Engagement - The company is inviting investors to submit questions before the event, with a deadline of May 12, 2022, at 12:00 [1] - Investors can submit their questions through a dedicated webpage [1] - The company will address commonly raised questions during the event [1] Group 4: Assurance of Information Disclosure - The company and its board members guarantee the authenticity, accuracy, and completeness of the disclosed information [1]

Financial Performance - Total revenue for Q1 2022 was ¥1,198,471,522.45, a decrease of 1.50% compared to ¥1,216,722,019.77 in the same period last year[4] - Net profit attributable to shareholders was ¥219,172,003.91, down 2.96% from ¥225,869,003.12 year-on-year[4] - Net profit excluding non-recurring gains and losses was ¥203,076,117.89, a decline of 5.60% from ¥215,120,160.37 in the previous year[4] - Net profit for the period was CNY 234,304,233.39, down from CNY 243,082,530.17 in the same period last year[26] - The net profit attributable to the parent company was 219,172,003.91, a decrease from 225,869,003.12, representing a decline of approximately 3.1%[29] - The total comprehensive income attributable to the parent company was 219,158,244.71, down from 225,888,266.00, reflecting a decrease of about 3.0%[29] - The basic and diluted earnings per share were both 0.38, compared to 0.39 in the previous period, indicating a decline of approximately 2.6%[29] Cash Flow - Net cash flow from operating activities increased by 94.87% to ¥430,597,673.80, compared to ¥220,961,896.05 in the same period last year[4] - Cash flow from operating activities generated a net amount of 430,597,673.80, an increase from 220,961,896.05, representing a growth of about 95.0%[33] - Cash inflow from investment activities was 355,539,307.25, up from 152,099,386.75, marking an increase of approximately 133.5%[36] - The net cash flow from investment activities was 25,527,371.83, a significant recovery from a negative cash flow of -81,082,611.47 in the previous period[36] - The net increase in cash and cash equivalents was 438,109,756.50, compared to a decrease of -33,670,023.55 in the prior period, indicating a turnaround[36] - The company's cash and cash equivalents at the end of the period amount to ¥1,763,281,813.20, an increase from ¥1,320,129,979.45 at the beginning of the year[15] - The total cash and cash equivalents at the end of the period reached 1,758,239,735.95, an increase from 1,614,236,608.43[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,745,185,918.48, reflecting a 1.95% increase from ¥5,635,203,544.61 at the end of the previous year[4] - The company's total assets increased to CNY 5,745,185,918.48 from CNY 5,635,203,544.61, marking a growth of 1.95%[22] - Total liabilities decreased to CNY 1,576,991,195.97 from CNY 1,700,079,714.65, a reduction of approximately 7.2%[22] - The total accounts receivable is ¥139,031,968.07, down from ¥194,746,659.98 at the beginning of the year[15] - Inventory at the end of the period is ¥550,568,874.73, a decrease from ¥709,638,552.08 at the beginning of the year[15] - The company reported a decrease in trading financial assets to ¥571,383,760.61 from ¥668,687,524.34[15] - Deferred income tax assets decreased to CNY 47,084,654.07 from CNY 55,780,116.02, a drop of about 15.6%[22] - The company maintained a stable short-term borrowing level at CNY 200,000,000.00, unchanged from the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,547[11] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of shares, totaling 265,200,000 shares[11] - The company has a pledged share amounting to 23,000,000 shares held by the largest shareholder[11] - The company has a shareholding plan involving employee stock ownership, with various shareholders holding small percentages[11] Investments and Expenses - Investment income rose by 51.41% to ¥369.36 million, attributed to increased investment in financial products[7] - The company reported a significant increase in cash flow from investment activities, up 131.48% to ¥2,552.74 million, primarily due to the redemption of financial products[7] - Total operating costs increased to CNY 924,211,409.04, up from CNY 906,568,193.56, reflecting a rise in sales expenses to CNY 321,201,460.89 from CNY 287,993,735.51[26] - Research and development expenses for the quarter were CNY 14,338,611.92, slightly up from CNY 13,792,037.35[26] Corporate Governance - The company has experienced changes in its board of directors, including the appointment of a new secretary[14] - The company has engaged in external investments, including fund subscriptions, as noted in multiple announcements[14] - The company has not undergone an audit for the first quarter report[37] Non-Recurring Items - Non-recurring gains and losses totaled ¥16,095,886.02 for the reporting period[6] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -13,759.20 compared to 19,262.88 previously[29]